Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2 - BMC Infectious Diseases User sacre_bae, in the CoronavirusDownunder subreddit, 19 Nov 2022